MARKET

KPTI

KPTI

Karyopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.67
-0.18
-1.52%
After Hours: 11.67 0 0.00% 16:14 09/17 EDT
OPEN
11.75
PREV CLOSE
11.85
HIGH
12.16
LOW
11.36
VOLUME
1.26M
TURNOVER
--
52 WEEK HIGH
19.19
52 WEEK LOW
3.920
MARKET CAP
722.61M
P/E (TTM)
-3.2867
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KPTI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

KPTI News

  • Karyopharm Signs $150M Royalty Agreement to Support Xpovio
  • Zacks.4h ago
  • CLASS ACTION UPDATE for NFLX, KPTI, GTT and EVH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  • GlobeNewswire.5h ago
  • SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
  • GlobeNewswire.16h ago
  • SHAREHOLDER ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019
  • ACCESSWIRE.1d ago

More

Industry

Biotechnology & Medical Research
-0.22%
Pharmaceuticals & Medical Research
+0.42%

Hot Stocks

Name
Price
%Change

About KPTI

Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from the Food and Drug Administration (FDA), in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Its XPOVIO is an oral SINE compound, which blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. It is also focused on developing treatments for other diseases, such as Hematologic Malignancies and Solid Tumor Malignancies.
More

Webull offers Karyopharm Therapeutics Inc (KPTI) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.